Juvenile idiopathic arthritis and risk of cancer before and after the introduction of biological therapies.

Children and adolescents with JIA are at a slightly increased risk of lymphoproliferative (but not of other) malignancies. At the group level, there is no sign that this risk has increased further after the introduction of bDMARDs.